CD8A and neoplasm: Furthermore, combination therapy with a PI3K inhibitor and LTB4 antagonist significantly improved the antitumour efficacy of the anti‐PD‐1 antibody, as both the PI3K inhibitor and LTB4 antagonist reversed the excluded TIME (cold tumours) into the inflamed TIME (hot tumours) with increased expression of PD‐L1 and highly activated CD8+ T cells.6, 26